- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Supporting Ph+ ALL Patient: Emotional Challenges and Quality of Life
The panel highlights the quality of life and emotional challenges faced by patients diagnosed with Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL).
EP: 1.Overview of Characteristics Unique to Ph+ ALL
EP: 2.Timely Detection: Incidence and Prevalence of Ph+ ALL
EP: 3.Supporting Ph+ ALL Patient: Emotional Challenges and Quality of Life
EP: 4.Screening and Diagnosing of Ph+ ALL in Adults
EP: 5.Diagnosis and Treatment Timeline: Different Phases of Ph+ ALL Management
EP: 6.Current Front-Line Targeted Treatments in Ph+ ALL
EP: 7.Prior Authorization and Access to Targeted Treatment for Ph+ ALL Patients
EP: 8.PhALLCON Trial: Efficacy and Safety of Ponatinib in Ph+ ALL Patients
EP: 9.Value-Based Care Models Optimizing Ph+ ALL Patient Care
EP: 10.Unmet Needs in Screening, Diagnosis, and Management of Ph+ ALL
EP: 11.Disparities in Access to Care for Ph+ ALL patients
EP: 12.The Future of Ph+ ALL Treatments
EP: 13.Concluding Thoughts on Ph+ ALL Treatment
The following is a video synopsis/summary of a Peer Exchange involving Ryan Haumschild, PharmD, MS, MBA, CPEL; Jonathon Abbas, MD; Vivian Tambe Tar, PharmD, MBA; Elias Jabbour, MD; and James McCloskey, MD.
The discussants focus on the impact of Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) and its treatment relating to patients' quality of life (QOL) and emotional well-being. Abbas noted the wide variation in patient age, from teenagers to octogenarians, each requiring personalized supportive care. The typically months-long treatment regimens with frequent clinic visits can be burdensome, especially for younger patients who may be building careers or families. Haumschild emphasized considering QOL goals, such as the ability to work and maintain mental health and relationships with loved ones. Monitoring QOL and adjusting care accordingly should be part of the treatment approach. The toxicity burden and its impact also require special attention in older patients with comorbidities. Overall, supporting patients with Ph+ ALL holistically emerges as a key priority.
Video synopsis is AI-generated and reviewed by AJMC editorial staff.
Using AI, Socioeconomic Factors to Predict Outcomes After Allo-SCT for AML
August 16th 2025Artificial intelligence (AI) and socioeconomic factors enhance risk stratification for patients with acute myeloid leukemia (AML) post transplant, aiming to reduce hospital readmissions and disease progression.
Read More
